Okomera

Pre-seed - July 2021

Okomera

Medtech, precision cancer medicine, microfluidics
Okomera is developing an innovative system to facilitate and accelerate the development of personalized cancer treatments. The company has developed a process that allows, for each patient, to test the effect of a panel of potential therapies (chemotherapies, immunotherapies, cell therapies, combined therapies) on the patient’s cells derived from tumor microbiopsy and cultured in 3D – spheroids – on microfluidic chips.

Founded by Aimee Wessel (PhD), Raphaël Tomasi (PhD), Sandra Jerström (PhD) and Charles Baroud (Pr. and PhD), the technology stems from LadHyX